Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01359007 · ClinicalTrials.gov registry record · Phase 2
FOLFIRINOX in Patients With Inoperable Pancreatic Cancer
A Phase 2 study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01359007 is a Phase 2 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 5 participants.
The verdict
NCT01359007, a Phase 2 study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The prognosis of patients with locally advanced unresectable pancreatic cancer is poor, and the median survival is less than 1 year. FOLFIRINOX therapy, which induces tumor downstaging sufficient to allow surgical resection, could improve the overall survival of patients with locally advanced pancreatic cancer. Based on the FOLFIRINOX regimen for advanced pancreatic cancer, a phase II study of this regimen in patients with locally advanced unresectable and borderline pancreatic cancer is planned to determine the rate of conversion to operability.
Interventions
- DRUG Irinotecan, Oxaliplatin, Leucovorin, 5-FU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01359007
The ClinicalTrials.gov registry entry for NCT01359007 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Irinotecan, Oxaliplatin, Leucovorin, 5-FU is the first listed.
NCT01359007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01359007 about?
NCT01359007 is a clinical study titled "FOLFIRINOX in Patients With Inoperable Pancreatic Cancer". The prognosis of patients with locally advanced unresectable pancreatic cancer is poor, and the median survival is less than 1 year. FOLFIRINOX therapy, which induces tumor downstaging sufficient to allow surgical resection, could improve the overall survival of patients with locally advanced pancre...
What is the current status of trial NCT01359007?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2011-05. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01359007?
The interventions under investigation include: Irinotecan, Oxaliplatin, Leucovorin, 5-FU (DRUG).
Who is sponsoring clinical trial NCT01359007?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.